UZ Leuven (University Hospitals Leuven) — part of KU Leuven; the largest hospital in Belgium

Number of service categories this organization offers.

• ✓1 service category listed

PubMed publications + ClinicalTrials.gov active trials linked to this organization.

• —0 PubMed publications
• —0 active clinical trials

How easy it is for patients and families to reach this organization.

• ✓Has website
• ✓Has phone number
• ✓Has email
• ✓Has street address
• ✓Has map coordinates

Breadth of direct support offered to patients and families.

• —In-person support groups
• —Online support groups
• —Caregiver resources in services
• —Funds or provides home care
• —Children's resources

Percentage of profile fields with information.

• ✓Name
• ✓Type
• ✓Country
• ✓State / region
• ✓Address
• ✓Phone
• ✓Email
• ✓Website
• ✓Mission

Connections to research consortia and ALS networks.

• —Part of a consortia
• —International reach
• —Publishes research
• —Maintains an ALS database
• ✓Mentions a known network (NEALS, ENCALS, TRICALS, etc.)

No community reviews yet — this dimension is excluded from the overall score.

• —No reviews yet

Contact

Mission

Lead: Prof. Philip Van Damme. National flagship ALS/MND diagnostic and multidisciplinary care center — the clinical arm of LEUCALS (Leuven Center for ALS). Lead: **Prof. Dr. Philip Van Damme**, MD, PhD — Professor of Neurology, KU Leuven; Neuromuscular Specialist, UZ Leuven Department of Neurology; Co-PI, Laboratory of Neurobiology (VIB-KU Leuven Center for Brain & Disease Research, Division of Experimental Neurology); neurology training KU Leuven, PhD 2004, neurology qualification 2006; visiting fellow MGH/Harvard Medical School (Day Neuromuscular Research Laboratory) 2008; FWO-Vlaanderen Clinical Investigatorship 2009–; leads Belgian TRICALS participation; co-initiator Project MinE Belgium.. Patient volume: largest Belgian ALS cohort; primary Belgian reporting site for Project MinE (500 of 853 Belgian patients sequenced via Leuven); major TRICALS participation site Clinical trial portfolio: Van Damme is co-author on Long-Term Tofersen in SOD1 ALS (Miller et al., *JAMA Neurology* 2026, 83(2):115-125); participates in international trials for FUS-ALS (ATXN2 repeat expansions), SMA clinical trials, C9orf72-associated ALS trials ERN Euro-NMD member — full ERN healthcare provider Research output: ~15% of ALS patients have identifiable monogenetic causes; LEUCALS focuses on genetic, biomarker, neuroimaging, and mechanism research (zebrafish, mouse, and iPSC-derived motor neuron disease models; organ-on-chip; 18F-FDG PET machine-learning classification of ALS subtypes)